Agile Therapeutics Inc. [AGRX] Stock trading around $2.70 per share: What’s Next?

Agile Therapeutics Inc. [NASDAQ: AGRX] stock went on an upward path that rose over 3.45% on Tuesday, amounting to a one-week price increase of more than 12.50%. The company report on July 21, 2020 that Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020.

Live Conference Call and Webcast at 4:30 p.m. ET.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced it will report second quarter 2020 financial results after the market close on Tuesday, August 11, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.

Over the last 12 months, AGRX stock rose by 171.36%. The average equity rating for AGRX stock is currently 1.60, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $240.19 million, with 76.65 million shares outstanding and 67.07 million shares in the current float. Compared to the average trading volume of 1.99M shares, AGRX stock reached a trading volume of 1059495 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Agile Therapeutics Inc. [AGRX]:

Janney have made an estimate for Agile Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 12, 2019. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on November 29, 2018, representing the official price target for Agile Therapeutics Inc. stock.

The Average True Range (ATR) for Agile Therapeutics Inc. is set at 0.14 The Price to Book ratio for the last quarter was 2.29, with the Price to Cash per share for the same quarter was set at 1.06.

AGRX Stock Performance Analysis:

Agile Therapeutics Inc. [AGRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.50. With this latest performance, AGRX shares dropped by -2.88% in over the last four-week period, additionally sinking by -27.81% over the last 6 months – not to mention a rise of 171.36% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGRX stock in for the last two-week period is set at 56.23, with the RSI for the last a single of trading hit 64.17, and the three-weeks RSI is set at 53.40 for Agile Therapeutics Inc. [AGRX]. The present Moving Average for the last 50 days of trading for this stock 2.72, while it was recorded at 2.56 for the last single week of trading, and 2.50 for the last 200 days.

Insight into Agile Therapeutics Inc. Fundamentals:

Return on Total Capital for AGRX is now -57.07, given the latest momentum, and Return on Invested Capital for the company is -56.45. Return on Equity for this stock declined to -56.45, with Return on Assets sitting at -51.73. When it comes to the capital structure of this company, Agile Therapeutics Inc. [AGRX] has a Total Debt to Total Equity ratio set at 0.38. Additionally, AGRX Total Debt to Total Capital is recorded at 0.37, with Total Debt to Total Assets ending up at 0.35.

Reflecting on the efficiency of the workforce at the company, Agile Therapeutics Inc. [AGRX] managed to generate an average of -$1,240,400 per employee.Agile Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 33.70 and a Current Ratio set at 33.70.

AGRX Stock EPS

With the latest financial reports released by the company, Agile Therapeutics Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AGRX.

Agile Therapeutics Inc. [AGRX] Insider Position Details

There are presently around $90 million, or 45.30% of AGRX stock, in the hands of institutional investors. The top three institutional holders of AGRX stocks are: PERCEPTIVE ADVISORS LLC with ownership of 15,919,325, which is approximately 33.552% of the company’s market cap and around 0.80% of the total institutional ownership; INVESTOR AB, holding 3,510,189 shares of the stock with an approximate value of $9.48 million in AGRX stocks shares; and VANGUARD GROUP INC, currently with $9.2 million in AGRX stock with ownership of nearly 30.484% of the company’s market capitalization.

Positions in Agile Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 52 institutional holders increased their position in Agile Therapeutics Inc. [NASDAQ:AGRX] by around 10,498,341 shares. Additionally, 21 investors decreased positions by around 4,743,188 shares, while 9 investors held positions by with 18,091,778 shares. The mentioned changes placed institutional holdings at 33,333,307 shares, according to the latest SEC report filing. AGRX stock had 32 new institutional investments in for a total of 3,056,751 shares, while 12 institutional investors sold positions of 1,682,511 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

87422

GIFT

Download free eBook for 

7 GROWTH  STOCKS FOR 2021

WAIT 
WE HAVE GIFT FOR YOU

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.